Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

BACKGROUND: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Garcia-Alfonso, Pilar, Chaves, Manuel, Muñoz, Andrés, Salud, Antonieta, García-Gonzalez, Maria, Grávalos, Cristina, Massuti, Bartomeu, González-Flores, Encarna, Queralt, Bernardo, López-Ladrón, Amelia, Losa, Ferran, Gómez, Maria Jose, Oltra, Amparo, Aranda, Enrique
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4423590/
https://ncbi.nlm.nih.gov/pubmed/25925749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1293-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars